{
    "name": "potassium phosphate/sodium acid phosphate",
    "comment": "Rx",
    "other_names": [
        "K-Phos M.F.",
        "K-Phos No. 2",
        "K-Phos Neutral",
        "Neutra-Phos",
        "Uro-KP Neutral"
    ],
    "classes": [
        "Electrolytes"
    ],
    "source": "https://reference.medscape.com/drug/k-phos-m-f-k-phos-no-2-potassium-phosphate-sodium-acid-phosphate-999540",
    "pregnancy": {
        "common": [
            "Pregnancy category: C",
            "Lactation: Unknown whether drug is distributed in breast milk; caution is advised"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Unknown whether drug is distributed in breast milk; caution is advised"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Patients with infected phosphate stones",
                "Severe renal impairment",
                "Hyperphosphatemia"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Patient may experience a mild laxative effect within first few days of therapy; if laxative effect persists, reduce the dose or discontinue use until diarrhea improves",
                "Use caution in cardiac disease, especially in digitalized patients with heart failure, patients with hypertension, renal calculi, renal impairment, rickets, adrenal insufficiency, acute dehydration, renal disease, extensive tissue breakdown, as in severe burns, myotonia congenita, cirrhosis of liver, edema, hypertension, hypoparathyroidism, acute pancreatitis, hepatic impairment, hypernatremia, metabolic alkalosis"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "sodium phosphate rectal",
            "description": {
                "common": "sodium phosphate rectal, sodium acid phosphate.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Either increases toxicity of the other. Coadministration of various sodium phosphate preparations are known to cause electrolyte disturbances and hypovolemia."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "baloxavir marboxil",
            "description": {
                "common": "sodium acid phosphate will decrease the level or effect of baloxavir marboxil by  cation binding in GI tract. Avoid or Use Alternate Drug. Baloxavir may bind to polyvalent cations resulting in decreased absorption. Studies in monkeys showed concurrent use with calcium, aluminum, or iron caused significantly decreased plasma levels. Human studies not conducted."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "erdafitinib",
            "description": {
                "common": "potassium phosphate, erdafitinib. Other (see comment). Avoid or Use Alternate Drug. \nComment: Avoid coadministration during initial dosing adjustment period (ie, first 21 days). Increases in serum phosphate levels are a pharmacodynamic effect of FGFR inhibition. Serum phosphate binders may obscure decisions regarding initial dosage increase."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "potassium phosphates, IV",
            "description": {
                "common": "potassium phosphate and potassium phosphates, IV both increase  serum potassium. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deflazacort",
            "description": {
                "common": "sodium acid phosphate and deflazacort both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dextroamphetamine",
            "description": {
                "common": "sodium acid phosphate decreases levels of dextroamphetamine by increasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lisdexamfetamine",
            "description": {
                "common": "sodium acid phosphate decreases levels of lisdexamfetamine by increasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "magnesium supplement",
            "description": {
                "common": "magnesium supplement will decrease the level or effect of potassium phosphate by  Other (see comment). Modify Therapy/Monitor Closely. Drug may form a chelate with divalent cations; may decrease absorption by the intestinal tract; applies to oral forms; separate administration of drugs to avoid interaction"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methamphetamine",
            "description": {
                "common": "sodium acid phosphate decreases levels of methamphetamine by increasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methylenedioxymethamphetamine",
            "description": {
                "common": "sodium acid phosphate decreases levels of methylenedioxymethamphetamine by increasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "omadacycline",
            "description": {
                "common": "sodium acid phosphate will decrease the level or effect of omadacycline by  inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "potassium iodide",
            "description": {
                "common": "potassium iodide and potassium phosphate both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pseudoephedrine",
            "description": {
                "common": "potassium phosphate decreases effects of pseudoephedrine by unknown mechanism. Use Caution/Monitor. Urinary excretion of indirect acting alpha/beta agonists (eg, pseudoephedrine) may increase when administered concomitantly with urinary acidifying agents, resulting in lower serum concentrations."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sarecycline",
            "description": {
                "common": "sodium acid phosphate will decrease the level or effect of sarecycline by  inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Confusion",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Gastrointestinal",
            "percent": null
        },
        {
            "name": "GI",
            "percent": null
        },
        {
            "name": "upset",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Low urine output",
            "percent": null
        },
        {
            "name": "Lower",
            "percent": null
        },
        {
            "name": "extremity swelling",
            "percent": null
        },
        {
            "name": "Mild laxative effect",
            "percent": null
        },
        {
            "name": "Numbness or tingling",
            "percent": null
        },
        {
            "name": "Shortness of breath",
            "percent": null
        },
        {
            "name": "Tachycardia",
            "percent": null
        },
        {
            "name": "Thirst",
            "percent": null
        },
        {
            "name": "Weakness or heaviness of legs",
            "percent": null
        },
        {
            "name": "Weight gain",
            "percent": null
        }
    ]
}